Zobrazeno 1 - 10
of 1 438
pro vyhledávání: '"Cisplatin-based chemotherapy"'
Autor:
María A. Ocampo-Gómez, María C. Moreno-Matson, David Ruiz-Londoño, Marino Cabrera, Rodolfo Varela
Publikováno v:
Urología Colombiana, Vol 33, Iss 2 (2024)
Objective: The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and III NSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomat
Externí odkaz:
https://doaj.org/article/1ce0b1b23af942098ca284ef7c3aec64
Publikováno v:
Cancer Medicine, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Background The current utilization of neurokinin‐1 receptor antagonists (NK1RAs) and the impact of updated guidelines on prescription patterns of antiemetic drugs among Chinese patients receiving highly emetogenic chemotherapy (HEC) remain
Externí odkaz:
https://doaj.org/article/f182e64fea1e4dae914042a9a3745677
Autor:
Chunkai Du, Mengmeng Zheng, Zhipeng Wang, Jian Zhang, Jun Lin, Lei Zhang, Ye Tian, Yichen Zhu
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background De novo urothelial carcinoma (UC) is a leading cause of death after kidney transplant (KT). The efficacy of various treatments, apart from surgery, and the prognosis for patients with urothelial carcinoma after kidney transplantat
Externí odkaz:
https://doaj.org/article/45e751bd4c154e54ac7b2d752877c266
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 519 (2024)
Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer (mUC) for more than two decades. However, many patients with comorbidities cannot receive cisplatin or its alternative, carboplatin. ‘Cisplatin-ineligible’
Externí odkaz:
https://doaj.org/article/377a74046c09489887e9cdd18dbe7230
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Shunsuke Owa, Takeshi Sasaki, Katsunori Uchida, Susumu Watanabe, Momoko Kato, Yusuke Sugino, Manabu Kato, Satoru Masui, Kouhei Nishikawa, Yuko Yoshio, Hideki Kanda, Yoshiki Sugimura, Takahiro Inoue
Publikováno v:
IJU Case Reports, Vol 4, Iss 5, Pp 267-271 (2021)
Introduction Adenocarcinoma of the rete testis is a rare malignancy with a poor prognosis. We report a case of adenocarcinoma of the rete testis with a durable response to cisplatin‐based chemotherapy. Case presentation A 48‐year‐old man with D
Externí odkaz:
https://doaj.org/article/75fb9d205e2b4d6c8281e1d48d678e8f
Autor:
Konstantinos Evmorfopoulos, Lampros Mitrakas, Athanasios Karathanasis, Ioannis Zachos, Vassilios Tzortzis, Panagiotis J. Vlachostergios
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1775 (2023)
Upper tract urothelial carcinoma (UTUC) is a rare malignancy, occurring in 5–10% of patients diagnosed with UC, and involves the renal pelvis, calyces, or ureters. UTUC can be sporadic or hereditary as a clinical manifestation of Lynch syndrome. Th
Externí odkaz:
https://doaj.org/article/095d2f80dfc2468bb9a8d62022e37b28
Autor:
Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Giuseppe Lucarelli, Daniela Terracciano, Daniela Pacella, Tommaso Muto, Angelo Porreca, Gian Maria Busetto, Francesco Del Giudice, Francesco Soria, Paolo Gontero, Francesco Cantiello, Rocco Damiano, Fabio Crocerossa, Abdal Rahman Abu Farhan, Riccardo Autorino, Mihai Dorin Vartolomei, Matteo Muto, Michele Marchioni, Andrea Mari, Luca Scafuri, Andrea Minervini, Nicola Longo, Francesco Chiancone, Sisto Perdona, Pietro De Placido, Antonio Verde, Michele Catellani, Stefano Luzzago, Francesco Alessandro Mistretta, Pasquale Ditonno, Vincenzo Francesco Caputo, Michele Battaglia, Stefania Zamboni, Alessandro Antonelli, Francesco Greco, Giorgio Ivan Russo, Rodolfo Hurle, Nicolae Crisan, Matteo Manfredi, Francesco Porpiglia, Giuseppe Di Lorenzo, Felice Crocetto, Carlo Buonerba
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThree or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycl
Externí odkaz:
https://doaj.org/article/2ba37d713d7a40cb85bfb53ae5a8709f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.